HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT01920802

Iloperidone and Olanzapine Compared With Placebo for Metabolic Effects

About this titleRead the official source — NCT01920802
Medication studyAges 18–35United StatesSchizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 35 years.

Listed locations
New YorkSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateNovember 2012
Recruitment status
Completed
Enrollment listed in the registry
31
Sponsor
New York State Psychiatric Institute
Sponsor type
Research institute
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 35 Years
Official registry ID
NCT01920802
Official title
Show the full official title

Quantitative Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking the Antipsychotic Medications Fanapt (Iloperidone) or Zyprexa (Olanzapine) or Placebo

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

New York

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is New York State Psychiatric Institute, a research institute.

Did this study involve medication?

Yes. The study involved medication, including olanzapine, iloperidone and Placebo.

Who was this study for?

Listed age limits: 18 years to 35 years.

Want to explore more studies?

Explore studies